Cape Bio Pharms, a spin-off company of the Biopharming Research Unit at the University of Cape Town, has partnered with international biotech companies to address the global accessibility problem for affordable reagents and rapid COVID-19 serology testing. Using plants to produce the antigens and antibodies required for rapid diagnostic test kits, Plants Against Corona initiative, aims to foster a faster, broader and more effective COVID-19 testing response, in South Africa and internationally. This is a key step in curbing pandemics and saving lives. To listen to the full interview, click here.
